Savara Inc (NASDAQ:SVRA) Receives Consensus Recommendation of “Buy” from Brokerages

Savara Inc (NASDAQ:SVRA) has been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.17.

Several research analysts recently commented on SVRA shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Savara in a report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Monday, September 9th. Oppenheimer boosted their price objective on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 26th. Finally, Guggenheim raised their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th.

Institutional Trading of Savara

A number of hedge funds have recently modified their holdings of the company. ProShare Advisors LLC raised its stake in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after purchasing an additional 2,114 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after buying an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Savara by 14.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after acquiring an additional 5,335 shares in the last quarter. Principal Financial Group Inc. increased its stake in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, CANADA LIFE ASSURANCE Co bought a new stake in Savara in the first quarter valued at about $35,000. Institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $4.24 on Monday. The business’s 50-day simple moving average is $4.34 and its 200-day simple moving average is $4.46. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. Savara has a 52 week low of $3.12 and a 52 week high of $5.70. The firm has a market cap of $585.92 million, a price-to-earnings ratio of -11.46 and a beta of 0.97.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, equities research analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.